This CME-accredited OncoBlast activity engages learners through a series of interactive, case-based questions covering the diagnosis, surveillance, prognostic markers, and evolving therapeutic strategies in Hodgkin and non-Hodgkin lymphomas. Participants will apply current clinical guidelines and emerging data to real-world decision-making, with a focus on personalized treatment selection, biomarker-driven therapy, and novel agents such as bispecific antibodies and targeted treatments.
Course Accreditations
Course Summary
| Events Starts | Events Ends |
|---|---|
| 1/1/2025 | 12/31/2025 |
Faculty
Christina Poh (MD)
Dr. Christina Poh is a hematologist-oncologist who specializes in the treatment of lymphomas and chronic lymphocytic leukemia (CLL). Her approach to care is based on candid, clear communication and teamwork. In addition to providing care, she is also an active clinical researcher. Dr. Poh's research interests include testing new drug combinations to improve effectiveness and decrease toxicity.
Disclosure
- Practicing medical oncologists/hematologists
- Medical oncology and hematology fellows
- Oncology nurses
- Nurse practitioners
- Physician assistants
- Pharmacists
Target Audience
- Identify guideline-based treatments for Hodgkin and non-Hodgkin lymphomas.
- Recognize key prognostic markers in lymphoid malignancies.
- Apply emerging therapies in relapsed/refractory lymphoma care.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: